Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512242 | 1.00 | PDE4A (0.66) | PDE4APDE4DPDE4BPDE4CSLC6A2 | |
| SCHEMBL8925196 | 0.90 | PDE4A (0.74) | PDE4APDE4DPDE4BPDE4CSLC6A2 | |
| SCHEMBL7925777 | 0.85 | PDE4A (0.60) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL7675692 | 0.85 | PDE4A (0.60) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6512654 | 0.84 | PDE4A (0.67) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6512648 | 0.84 | PDE4A (0.67) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6886847 | 0.81 | PDE4A (0.86) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6886848 | 0.81 | PDE4A (0.86) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6509812 | 0.81 | PDE4A (0.63) | PDE4APDE4DPDE4BPDE4CSLC6A2 | |
| SCHEMBL6509817 | 0.81 | PDE4A (0.63) | PDE4APDE4DPDE4BPDE4CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0766669-B1 | TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH R&D LTD (GB) | 2005-04-20 | — | — | EP | disclosed |
| US-20020143011-A1 | Tri-substituted phenyl derivatives and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED | 2002-10-03 | — | — | US | disclosed |
| US-6245774-B1 | ANTIINFLAMMATORY AGENTS; BRONCHODILATOR AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-06-12 | — | — | US | disclosed |
| EP-0766669-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-04-09 | — | — | EP | disclosed |
| WO-1995035283-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143011-A1 | Tri-substituted phenyl derivatives and processes for their preparation | CBR1, NCOR1, CNR1 | PDE4A 4775/4885PDE4D 4857/4885PDE4B 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.